Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $8.00 price target on the stock.
Werewolf Therapeutics Full Year 2024 Earnings: EPS Misses Expectations [Yahoo! Finance]
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]